Tags

Type your tag names separated by a space and hit enter

3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics.
J Med Virol. 2020 10; 92(10):2114-2123.JM

Abstract

The present study provides the first multiepitope vaccine construct using the 3CL hydrolase protein of SARS-CoV-2. The coronavirus 3CL hydrolase (Mpro) enzyme is essential for proteolytic maturation of the virus. This study was based on immunoinformatics and structural vaccinology strategies. The design of the multiepitope vaccine was built using helper T-cell and cytotoxic T-cell epitopes from the 3CL hydrolase protein along with an adjuvant to enhance immune response; these are joined to each other by short peptide linkers. The vaccine also carries potential B-cell linear epitope regions, B-cell discontinuous epitopes, and interferon-γ-inducing epitopes. Epitopes of the constructed multiepitope vaccine were found to be antigenic, nonallergic, nontoxic, and covering large human populations worldwide. The vaccine construct was modeled, validated, and refined by different programs to achieve a high-quality three-dimensional structure. The resulting high-quality model was applied for conformational B-cell epitope selection and docking analyses with toll-like receptor-3 for understanding the capability of the vaccine to elicit an immune response. In silico cloning and codon adaptation were also performed with the pET-19b plasmid vector. The designed multiepitope peptide vaccine may prompt the development of a vaccine to control SARS-CoV-2 infection.

Authors+Show Affiliations

Centre for Medical Biotechnology, Maharshi Dayanand University, Rohtak, Haryana, India.Centre for Biotechnology, Maharshi Dayanand University, Rohtak, Haryana, India.Centre for Medical Biotechnology, Maharshi Dayanand University, Rohtak, Haryana, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32379348

Citation

Jakhar, Renu, et al. "3CL Hydrolase-based Multiepitope Peptide Vaccine Against SARS-CoV-2 Using Immunoinformatics." Journal of Medical Virology, vol. 92, no. 10, 2020, pp. 2114-2123.
Jakhar R, Kaushik S, Gakhar SK. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics. J Med Virol. 2020;92(10):2114-2123.
Jakhar, R., Kaushik, S., & Gakhar, S. K. (2020). 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics. Journal of Medical Virology, 92(10), 2114-2123. https://doi.org/10.1002/jmv.25993
Jakhar R, Kaushik S, Gakhar SK. 3CL Hydrolase-based Multiepitope Peptide Vaccine Against SARS-CoV-2 Using Immunoinformatics. J Med Virol. 2020;92(10):2114-2123. PubMed PMID: 32379348.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics. AU - Jakhar,Renu, AU - Kaushik,Samander, AU - Gakhar,Surendra K, Y1 - 2020/05/22/ PY - 2020/03/26/received PY - 2020/05/05/accepted PY - 2020/5/8/pubmed PY - 2020/12/30/medline PY - 2020/5/8/entrez KW - 3CL hydrolase KW - COVID-19 KW - SARS-CoV-2 KW - immunoinformatics KW - multiepitope KW - peptide vaccine SP - 2114 EP - 2123 JF - Journal of medical virology JO - J Med Virol VL - 92 IS - 10 N2 - The present study provides the first multiepitope vaccine construct using the 3CL hydrolase protein of SARS-CoV-2. The coronavirus 3CL hydrolase (Mpro) enzyme is essential for proteolytic maturation of the virus. This study was based on immunoinformatics and structural vaccinology strategies. The design of the multiepitope vaccine was built using helper T-cell and cytotoxic T-cell epitopes from the 3CL hydrolase protein along with an adjuvant to enhance immune response; these are joined to each other by short peptide linkers. The vaccine also carries potential B-cell linear epitope regions, B-cell discontinuous epitopes, and interferon-γ-inducing epitopes. Epitopes of the constructed multiepitope vaccine were found to be antigenic, nonallergic, nontoxic, and covering large human populations worldwide. The vaccine construct was modeled, validated, and refined by different programs to achieve a high-quality three-dimensional structure. The resulting high-quality model was applied for conformational B-cell epitope selection and docking analyses with toll-like receptor-3 for understanding the capability of the vaccine to elicit an immune response. In silico cloning and codon adaptation were also performed with the pET-19b plasmid vector. The designed multiepitope peptide vaccine may prompt the development of a vaccine to control SARS-CoV-2 infection. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/32379348/3CL_hydrolase_based_multiepitope_peptide_vaccine_against_SARS_CoV_2_using_immunoinformatics_ L2 - https://doi.org/10.1002/jmv.25993 DB - PRIME DP - Unbound Medicine ER -